Clinical Trials Logo

Amyloidosis clinical trials

View clinical trials related to Amyloidosis.

Filter by:

NCT ID: NCT02713880 Withdrawn - Clinical trials for Transthyretin Amyloidosis

Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy (BioTRAP)

BioTRAP
Start date: August 20, 2018
Phase:
Study type: Observational

International, multicenter, observational, longitudinal study to identify biomarker/s for the development of a new MS-based biomarker for the early and sensitive diagnosis of Transthyretin-Related Familial Amyloidotic Polyneuropathy from blood and number of correctly identified patients with Transthyretin-Related Familial Amyloidotic Polyneuropathy

NCT ID: NCT02664571 Withdrawn - Alzheimer Disease Clinical Trials

Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis

FBB ACC
Start date: July 2020
Phase: N/A
Study type: Interventional

The main objective of this study is to compare the distribution of Florbetaben (NEURACEQ: FBB) in the brain in amyloid cerebral angiopathy (ACA) manifested by isolated hemosiderosis in non-demented patients with that observed in healthy subjects, patients with ACA and with lobar hematoma(s) and patients with Alzheimer's dementia without MRI signs in favor of ACA.

NCT ID: NCT02627820 Withdrawn - Amyloidosis Clinical Trials

The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart

Start date: January 2016
Phase: Phase 2
Study type: Interventional

ATTRwt (also known as senile systemic, or senile cardiac amyloidosis) is a progressive heart disease, causing congestive heart failure. It is caused by amyloid protein deposits in the heart, that are derived from a normal protein, TTR, made in the liver. The aim of the study is to determine whether lowering the blood levels of TTR, by a weekly injection of a compound designed specifically to do this, will slow the progression of the disease when treated patients are compared to previously-followed patients who were not receiving this drug. The study also aims to determine how well this drug is tolerated and the existence and severity of any drug side-effects.

NCT ID: NCT02589860 Withdrawn - Multiple Myeloma Clinical Trials

Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant

Start date: October 30, 2015
Phase:
Study type: Observational

This is a pilot study to explore and identify changes in molecular processes within the oral mucosa that are associated with the development of oral mucositis (OM) in patients treated with Melphalan who undergo autologous peripheral blood stem cell transplantation.

NCT ID: NCT02535962 Withdrawn - Pharyngitis Clinical Trials

Probiotics and Corticosteroids for Treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA)

PFAPA
Start date: October 2016
Phase: Phase 2
Study type: Interventional

The purpose of study is to see if adding probiotics to corticosteroid treatment for children with PFAPA could improve the health and daily of patients through reduction in febrile period frequency and length, along with concomitant reduction of associated symptoms. Current standard of care incorporates the administration of corticosteroids; however, while limiting the symptoms associated with PFAPA, corticosteroid use has been shown to increase the frequency at which these symptoms occur. Investigators hypothesize that administration of probiotics along with corticosteroids will work to decrease the frequency at which the febrile episodes occur. Additionally, probiotics may decrease the maximal fever experienced during these episodes, amount of corticosteroid needed to control the symptoms, average length of the episodes, and the number of patients who ultimately undergo tonsillectomy due to unsuccessful treatment with medication.

NCT ID: NCT02462213 Withdrawn - Cardiomyopathies Clinical Trials

Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging

PICA-CMR
Start date: October 2013
Phase: N/A
Study type: Observational

Cardiac amyloidosis describes a process by which abnormally folded proteins infiltrate the heart tissue. Given the insidious nature of this disease process, diagnosis is often too late for a meaningful intervention. Advances in the treatment of the amyloidoses have improved outcomes for patients with these conditions. The focus of this study is to identify the involvement of the heart, most closely associated with mortality, so that aggressive management can be instituted improving prognosis.

NCT ID: NCT02152644 Withdrawn - Clinical trials for Amyloid Neuropathy, Carpal Tunnel

Prevalence of Amyloidosis and Carpal Tunnel

Start date: June 1, 2017
Phase:
Study type: Observational

This is a cross sectional study to estimate the prevalence of the presence of amyloid deposits in a biopsy of subcutaneous fat cell, carpal flexor retinaculum and synovial tissue sheath of the flexor tendons requirement for carpal tunnel surgery.

NCT ID: NCT01531751 Withdrawn - Clinical trials for Primary Amyloidosis of Light Chain Type

High Cut-off Hemodialysis in Patients With Advanced Cardiac AL Amyloidosis and End Stage Renal Disease

DIACAL
Start date: February 2015
Phase: Phase 2
Study type: Interventional

The aim of the study is to assess survival of patients with advanced cardiac AL amyloidosis treated with high cut-off hemodialysis (HCO-HD) combined with chemotherapy.

NCT ID: NCT00186095 Withdrawn - Amyloidosis Clinical Trials

Mixed Chimeric Transplantation for Primary Amyloidosis

Start date: December 2000
Phase: N/A
Study type: Interventional

To evaluate the role of nonmyeloablative allogeneic transplantation in Amyloidosis.